Co-Dx
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Utah, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2401 S Foothill Dr Ste D, Salt Lake City...Phone Number
(801) 438-1036Website
www.co-dx.comRevenue
<$5 MillionStock Symbol
CODXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Co-Dx
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2Read more
Co-Dx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Co-Dx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Co-Dx is spiking on competitors!
Check if Co-Dx has recently received funding, and reach out quickly before it becomes old news!
Click to see if Co-Dx had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Co-Dx
Funding: Get notified immidiatlly once Co-Dx has new funding data
Earning: See what the market has to say on Co-Dx recently announced quarterly report
Co-Dx, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Co-Dx launches new products
Recommended Actions
Find VP level buyers at Co-Dx
Find more new buyers
Company Profile Activity
Activity Insights
Co-Dx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Co-Dx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Co-Dx.
Co-Dx financials insights
Gather financial insights about Co-Dx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$750K
2017
Stock Offering
$7.1M
2023
Grant
$2.3M
2026
Stock/Share Issuance
$3M
Co-Dx Tech Stack
A closer look at the technologies used by Co-Dx
See more technologies
Most Recent Scoops
Funding
Funding
Facilities Relocation / Expansion
Co-Dx announced that its CoMira joint venture is progressing toward operational readiness, including finalizing a lease for a manufacturing facility in Saudi Arabia, as part of its strategy to expand across Saudi Arabia and 18 additional MENA markets.
Leasing, Corporate Strategy, Manufacturing Operations
Earnings
Co-Dx has reported total operating expenses of $50.6 million for the full year 2025, compared to $43.0 million in 2024, with the increase primarily driven by a non-cash impairment charge of approximately $18.9 million related to in-process research and development intangible assets; excluding this charge, operating expenses declined year-over-year.
Earnings, Research & Development, Finance
Earnings
Co-Dx has reported a net loss of $46.9 million, or $35.25 per share, for the full year 2025, compared to a net loss of $37.6 million, or $37.22 per share, in 2024, with Adjusted EBITDA improving to a loss of $28.0 million from a loss of $33.5 million in the prior year.
Earnings, Finance
Project
Product Development, Clinical Operations
Co-Dx News & Media
Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a...Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regions Potential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-care platform capabilities SALT LAKE CITY, June 2, 2026 /PRNewswire/ -- Co-Diagnostics,...Is Co-Diagnostics National Security’s Next Diagnostic Pick?
Global health emergencies are shifting sovereign biodefense strategies toward decentralized diagnostic networks capable of deploying rapid stockpiles.Co-Diagnostics Raises $3.0 Million in Private Placement; Investors Get Registration Rights
Co-Diagnostics announced a $3.0 million private placement to fund working capital and general corporate purposes. The financing includes common shares, immediately exercisable pre-funded warrants, and five-year common warrants, with purchase prices of $1.821 per common share and $1.8209 per pre-fun…
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Co-Dx
Sign Up For FreeTo access detailed company insights
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-c... Read More
